-
Treatment with Bortezomib of human CD4. T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Caballero-Velázquez T, Gutiérrez-Cossío S, Hernández-Campo P, Diez-Campelo M, Herrero-Sánchez C, Rodríguez-Serrano C, Santamaría C, Sánchez-Guijo FM, del Cañizo C, San Miguel JF. Haematologica 94(7):975-83. FI: 6.416 (Q1) Update on treatment recommendations from the fourth international workshop on Waldenstrom's macroglobulinemia Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V, Fermand JP, Merlini G, Morel P, Morra E, Ocio EM, Owen R, Ghobrial IM, Seymour J, Kyle RA, Treon SP. Journal of Clinical Oncology 27(1):120-6. FI: 17.793 (Q1) VMP (Bortezomib, Melphalan and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function and results in reversal of renal impairment: cohort analysis of the phase III VISTA study Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpliberg O, Kastritis E, Kropff M, Petrucci MY, Delforge M, Alexeeva J, Schots R, Masszi T, Mateos MV, Deraedt W, Liu K, Cakana A, van de Velde H, San Miguel JF. Journal of Clinical Oncology 27(36):6086-93. FI: 17.793 (Q1) Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double strand breaks Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernández S, San Segundo L, Vilanova D, Lopez-Corral L, Montero JC, Hernandez-Iglesias T, de Alava E, Galmarini C, Avilés P, Cuevas C, San Miguel JF, Pandiella A. Blood 113(16):3781-91. FI: 10.555 (Q1)
-
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garayoa M, Vilanova D, Montero JC, Mitsiades N, McMullan CJ, Munshi NC, Hideshima T, Chauhan D, Aviles P, Otero G, Faircloth G, Mateos MV, Richardson PG, Mollinedo F, San-Miguel JF, Anderson KC. Cancer Research 68(13):5216-25. FI: 7.543 (Q1) Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphims of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphisms analysis Sarasquete ME, García-Sanz R, Marín L, Alcoceba M, Chillón MC, Balanzategui A, Santamaría C, Rosiñol L, de la Rubia J, Hernández MT, García-Navarro I, Lahuerta JJ, González M, San Miguel JF. Blood 112(7):2709-12. FI: 10.555 (Q1) Bortezomib is associated with better health related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, Crawford B, Massaro J, Dhawan R, Gupta S, Anderson KC. British Journal of Haematology 143(4):511-9. FI: 4.597 (Q1) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, García-Sánchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Haematologica 93(4):560-5 FI: 6.416 (Q1) Characterization of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma Lonial S, Richardson PG, San Miguel JF, Sonneveld P, Schuster MW, Bladé J, Cavenagh J, Rajkumar SV, Jakubowiak AJ, Esseltine DL, Anderson KC, Harousseau JL British Journal of Haematology 143(2):222-9. FI: 4.597 (Q1) Clinical impact of human Jurkat T-cell-line¿derived antithumocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation Ayuk F, Pérez-Simón JA, Shimoni A, Sureda A, Zabelina T, Schwerdtfeger R, Martino R, Sayer HG, Alegre A, Lahuerta JJ, Atanackovic D, Wolschke C, Nagler A, Zander AR, San Miguel JF, Kröger N Haematologica 93(9):1343-50. FI: 6.416 (Q1)
|
